EXOZYMES INC.
Close on Oct 19, 2026
- Market cap
- $34.64M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Exozymes has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Exozymes filed with the SEC
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Closing of $6 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Pricing of Public Offering of Common Stock and Warrants
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
advancing commercial readiness with profound production metrics on initial NCT pilot run
Other events · EX-99.1 to Form 8-K
eXoZymes achieves 100× scale-up of NCT production
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
Provides Fourth Quarter and Full Year 2024 Update
Other events · EX-99.1 to Form 8-K
appoints experienced biomanufacturing executive, Damien Perriman, as CCO
Other events · EX-99.1 to Form 8-K
Technologies Announces Pricing of $15 Million Initial Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Technologies Announces Closing of Initial Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K